{"id":"W3153813300","doi":"10.1053/j.gastro.2021.03.065","title":"Challenges and Opportunities in IBD Clinical Trial Design","year":2021,"lang":"en","type":"article","venue":"Gastroenterology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Janssen Pharmaceuticals; National Institute of Diabetes and Digestive and Kidney Diseases; Cumming School of Medicine, University of Calgary; Perelman School of Medicine, University of Pennsylvania; University of California, San Diego; Humanitas Research Hospital; Chinese University of Hong Kong; University of Oxford; Cedars-Sinai Medical Center; Barts Health NHS Trust; All-India Institute of Medical Sciences; KU Leuven; Harvard School of Dental Medicine; University of Miami; Icahn School of Medicine at Mount Sinai; Pfizer; Northwestern University; Universitaire Ziekenhuizen Leuven, KU Leuven; Dartmouth College; Bristol-Myers Squibb; British Heart Foundation; Takeda Pharmaceutical Company; AbbVie; University of Pennsylvania; Roche; Mayo Clinic; Boehringer Ingelheim; Amgen; Tillotts Pharma; Amsterdam University Medical Centers; EA Pharma Co., Ltd.; Gilead Sciences","keywords":"Clinical trial; Medicine; Scopus; Inflammatory bowel disease; Clinical study design; Family medicine; Alternative medicine; Disease; MEDLINE; Internal medicine; Pathology; Political science","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004527054,0.0001002894,0.00016045,0.00002996695,0.00001708013,0.000007107725,0.00007822141,0.0001306929,0.00001808555],"category_scores_gemma":[0.0001256875,0.0001068279,0.00005632738,0.000007054614,0.0001254838,0.000002647249,0.0001272902,0.00008918814,0.000003637322],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00000432338,"about_ca_system_score_gemma":0.00007544321,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":4.489633e-7,"about_ca_topic_score_gemma":0.0001422472,"domain_scores_codex":[0.9984976,0.0006346644,0.0002677987,0.0003196468,0.00004668503,0.000233581],"domain_scores_gemma":[0.9995618,0.00001967375,0.00005137527,0.0002330318,0.00003814376,0.00009598092],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4930254,0.002960219,0.3223538,0.0002323406,0.0008385865,0.01451458,0.0006158454,0.0001288735,0.01968262,0.003406679,0.01042409,0.131817],"study_design_scores_gemma":[0.07801419,0.005347368,0.8994195,0.00002627714,0.00005924159,0.000355508,0.0005585291,0.00008519417,0.000728572,0.0005880261,0.01451631,0.0003012568],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970381,0.0009553597,0.0003613705,0.0008091308,0.0002666911,0.000134605,0.000004202946,0.000006965172,0.0004235929],"genre_scores_gemma":[0.9930192,0.004704902,0.0005284895,0.001248919,0.0002779191,0.00003664485,0.00003246238,0.00001317877,0.0001383353],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5770657,"threshold_uncertainty_score":0.4356315,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1249780573605359,"score_gpt":0.3235925913911219,"score_spread":0.198614534030586,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}